Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice

NCT02740218 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02740218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02740218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
June 30, 2016
Completion date
October 27, 2021
Enrollment
610 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis